Browsing Tag
Ulcerative colitis
30 posts
Teva and Sanofi reveal promising Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceutical Industries Ltd. and Sanofi have unveiled encouraging new data from their Phase 2b RELIEVE UCCD trial,…
AbbVie to acquire Landos Biopharma to bolster autoimmune disease treatments
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic…
EMA accepts MAA for Dong-A ST’s Stelara biosimilar, DMB-3115
Dong-A ST, the South Korean pharmaceutical company, has received confirmation from the European Medicine Agency (EMA) of the…
Zydus Lifesciences gets FDA final approval for Balsalazide Disodium Capsules
Zydus Lifesciences, along with its subsidiaries and affiliates, has achieved a significant milestone with the final approval from…
Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around…
Roivant Sciences, Pfizer create new business for inflammatory disease drug
Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605…
Alembic Pharmaceuticals secures FDA final approval for generic mesalamine extended-release capsules for ulcerative colitis remission
Alembic Pharmaceuticals gains US FDA approval for its generic mesalamine extended-release capsules, targeting the $133M ulcerative colitis market.
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo…
AzurRx BioPharma acquires US biotech company First Wave Bio for $229m
AzurRx BioPharma has signed a stock and cash deal worth $229 million to acquire Florida-based clinical-stage biotech company…
Zydus Cadila secures US FDA approval for Mesalamine Extended-Release Capsules for ulcerative colitis remission maintenance
Zydus Cadila gets US FDA approval for Mesalamine Extended-Release Capsules 0.375g to maintain ulcerative colitis remission, strengthening its US generics portfolio.